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Abstract
Accumulating evidence suggests that cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid into
epoxyeicosatrienoic acids (EETs) which play important roles in various pathophysiological processes. Interestingly,
CYP-derived eicosanoids are vasodilatory, at least in part through their ability to activate eNOS and subsequent NO
release. This study investigated the roles of eNOS in CYP2J3 gene delivery reducing blood pressure and improving
insulin resistance in fructose-treated rats. CYP2J3 overexpression in vivo increased EET generation, reduced blood
pressure and reversed insulin resistance as determined by insulin resistance index (HOMA-IR). Furthermore,
administration of eNOS inhibitor L-NMMA significantly and partially abolished the beneficial effects of CYP2J3 gene
delivery on hypertension and insulin resistance induced by fructose intake, and possible mechanism is associated
with increased ET-1, ETA-receptor mRNA expression and reduced sensitivity of insulin to peripheral tissues and
organs characterized by reduced activity of IRS-1/PI3K/AKT and AMPK signalling pathways. These data provide
direct evidence that CYP2J3-derived EETs may alleviate insulin resistance at least in part through upregulated eNOS
expression.
Introduction
In vascular endothelium, Nitric oxide (NO) is produced by
a constitutively expressed enzyme known as endothelial
nitric oxide synthase (eNOS), which converts L-arginine
to L-citrulline [1]. A great amount of evidences implicate
NO plays an important role in controlling vascular tone
and modulating blood flow to organs [1]. Interestingly,
experimental evidences suggest that NO is involved in the
pathogenesis of insulin resistance and diabetes. eNOS
activity and the production of NO are chronically impaired
in type 2 diabetes [2]. Decreased eNOS activity has been
observed in both aortic endothelium and cardiac tissue of
fructose-treated rats [3], and furthermore exogenous insu-
lin therapy appears to improve endothelial function in
patients with type 2 diabetes [4]. Our previous data indi-
cated that fructose intake induced increased blood pres-
sure, insulin resistance and downregulation of eNOS
expression, and eNOS overexpression significantly
decreased fructose-induced hypertension and insulin resis-
tance in rats [5]. Taken together, these data suggest that
insulin resistance and diabetes are characterized partly by
endothelial dysfunction and potentially by altered eNOS
expression and NO production.
It is well known that cytochrome P450 (CYP) epoxy-
genases metabolized arachidonic acid into four different
cis-epoxyeicosatrienoic acids (EETs): 5,6-, 8,9-, 11,12-,
and 14,15-EET. Human P450 2J2 (CYP2J2) and its rat
homolog CYP2J3 are predominant enzymes responsible
for the oxidation of endogenous arachidonic acid pools
in vascular endothelium, cardiac myocytes, pancreas,
and other tissues where they exert regulatory effects in
normal and pathophysiological processes [6].
Accumulating evidence suggests that EETs play crucial
and diverse roles in cardiovascular homeostasis. CYP
epoxygenases and EETs upregulate eNOS expression and
phosphorylation in bovine aortic endothelial cells via
activation of Mitogen-activated protein kinase (MAPK),
protein kinase C, and phosphatidylinositol 3-kinase
(PI3K)/AKT signaling pathways [7,8]. Our previous study
indicated that CYP2J3 overexpression significantly
reduced insulin resistance, decreased blood pressure and
prevented eNOS downregulation induced by fructose
intake [9], and possibly CYP2J3 gene delivery reduced
blood pressure through upregulated eNOS expression
and downregulated endothelin-1 (ET-1) and endothelin
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receptor A (ETA) expression. Furthermore, CYP2J3 over-
expression significantly improved insulin resistance, at
least in part through eNOS, IRS-1, and PI3K/AKT signal-
ing pathways, as well as adenosine monophosphate-acti-
vated protein kinase (AMPK) signaling pathways in liver,
muscle, heart, and kidney [9]. Interestingly, CYP-derived
eicosanoids are vasodilatory, at least in part through their
ability to activate eNOS and subsequent NO release [10],
however, whether CYP2J3 overexpression can decrease
blood pressure and reduce insulin resistance induced by
fructose via eNOS is still not completely clear.
In this study, we hypothesized that overexpression of
CYP2J3 and the subsequent increase in production of
EETs might attenuate hypertension and insulin resis-
tance via upregulation of eNOS. Thus, the present study
investigated the roles of eNOS in CYP2J3 gene delivery
reducing blood pressure and improving insulin resis-
tance in fructose-treated rats.
Research design and methods
Materials
Polyclonal antibodies to b-actin, PI3K, AKT, phosphory-
lated AKT (P-AKT), AMPK, phosphorylated AMPK
(P-AMPK), insulin receptor substrate-1 (IRS-1), phos-
phorylated IRS-1, and eNOS were from Santa Cruz Bio-
technology Inc. (Santa Cruz, CA); goat anti-rabbit, goat
anti-mouse and rabbit anti goat horseradish peroxidase-
conjugated secondary antibody were obtained from
Sigma-Aldrich (St. Louis, MO); Enhanced chemilumines-
cence substrate (SuperSignal Substrate) was product of
PIERCE (Rockford, IL); Plasmid purification kits from
GIBCO (Grand Island, NY); Fructose, glucose, triglyceride
and cholesterol reagents were purchased from Ningbo
Chicheng Biocompany (Ningbo, China). 14,15-DHET
ELISA Kit from Detroit R&D Inc. NG-Monomethyl-L-
Arginine (L-NMMA) was from Sigma-Aldrich (St. Louis,
MO); All other chemicals and reagents were purchased
from Sigma-Aldrich unless otherwise specified. A full-
length of CYP2J3 cDNA were cloned from rat liver RNA
and then subcloned into plasmid of pcDNA3.1 in sense
(p2J3(+)), and pcDNA-CYP2J3(+) was a generous gift
from Dr. Zeldin (National Institute of Environmental
Health Sciences, National Institutes of Health), specifically,
we have re-sequenced it, and the results indicated that the
sequence was correct.
Animals
All animal experimental protocols were approved by
The Academy of Sciences of China and complied with
standards stated in the NIH Guidelines for the Care and
Use of Laboratory Animals. Male Sprague-Dawley rats
weighing 180 ± 20 g were obtained from the Experi-
mental Animal Center of Shanghai (Shanghai, PRC).
Experimental animals were housed at 25°C with 12 hour
light/dark cycles and a relative humidity of 50% and
allowed free access to normal chow and water through-
out the study period. Animals were randomly assigned
to different treatment groups and subjected to a one-
week adaptation period.
Fructose feeding protocol and gene delivery
Rats were randomly assigned to different treatment
groups and subjected to a one-week adaptation period
for systolic blood pressure measurement via the tail-cuff
method as described below. Following this (i.e. beginning
at week 0), rats were fed normal rat chow and either
water (n = 10) with or without containing 10% fructose
(n = 40) for a total of 6 weeks. Systolic blood pressure
was measured weekly until week 6, and gene delivery
protocols were undertaken at week 3 as described pre-
viously [9]. Briefly, 3 weeks after fructose feeding, rats
were anesthetised with ethylether and received sublingual
vein injections of various vectors dissolved in 0.9% NaCl
(at 1 mg/ml) at a dose of 5 mg/kg body weight. Normal-
treated rats received injection of 0.9% NaCl (Normal).
Fructose-treated rats were further divided into four
groups: Fructose (fructose+pcDNA3.1); Fructose+L-
NMMA (fructose+pcDNA3.1+L-NMMA; L-NMMA
(100mg/Kg.d) was given by gavage from the beginning of
fructose drinking to the end of the study); Fructose
+pcDNA-CYP2J3(+) (received injection of pcDNA-
CYP2J3(+)); Fructose+pcDNA-CYP2J3(+)+L-NMMA (n
= 8 for each group).
Blood pressure measurement
Blood pressure was measured as described previously
[9]. In brief, systolic blood pressure was measured
weekly in conscious rats with a manometer-tachometer
(Rat Tail NIBP System, ADI Instruments, Australia)
using the tail-cuff method. Rats were placed in a plastic
holder mounted on a thermostatically controlled warm
plate that was maintained at 35°C during measurements.
An average value from 5 blood pressure readings (that
differed by no more than 2 mmHg) was determined for
each animal after they became acclimated to the envir-
onment. All blood pressure measurements were made
between 09:00 h and 12:00 h.
Serum and urine analysis
Just prior to gene delivery at week 3 of the study,
approximately 0.5 ml of blood was drawn from the tail
vein of each rat. After coagulation, serum was collected
by centrifugation and stored at -80°C. Urine samples
were collected over a 24-hour period prior to gene
delivery as described previously [9]. Three weeks after
gene delivery (i.e. at week 6 of the study), serum and
urine samples were collected and analyzed in a similar
manner from 10 rats from each of the above groups.
Xu et al. Cardiovascular Diabetology 2011, 10:114
http://www.cardiab.com/content/10/1/114
Page 2 of 10
Serum glucose, serum cholesterol, serum triglyceride,
Serum insulin levels, serum LDL-C, serum HDL-C, and
urinary osmolarity were measured as described before
[9], and insulin resistance was calculated using the
homeostasis model assessment (HOMA-IR = fasting
glucose × fasting insulin/22.5) method. We measured
serum nitric oxide (NO) concentrations using the Griess
method.
Evaluation of plasma and urine 14,15-DHET by ELISA
To assess in vivo EET production, an ELISA kit (Detroit
R&D) was used to determine concentrations of the
stable EET metabolite 14,15-dihydroxyeicosatrienoic
acid (14,15-DHET) in the plasma and urine of rats.
Briefly, eicosanoids were extracted from the plasma and
urine samples three times with ethyl acetate after acidifi-
cation with acetic acid (to convert EETs into DHETs).
After evaporation, saponification with 0.4N KOH in
methanol and re-extraction, 14,15-DHET was dissolved
in 30 μl DMF and quantified by ELISA according to the
manufacturer’s instructions as previously described [9].
Western blot analysis
Three weeks after gene injection, rats from each group
were anesthetised with pentobarbital (100 mg/kg i.p.)
and skeletal muscles, aortas, hearts, kidneys and livers
were excised, frozen in liquid nitrogen and stored at
-80°C. Related protein expression was determined by
western blot as described previously [9]. In brief, tissue
proteins were extracted using TRIZOL reagent and pro-
tein concentrations were estimated by the Bradford
method. Twenty micrograms of protein per lane were
separated with 10% SDS/PAGE gels and electrophoreti-
cally transferred onto PVDF membranes. Membranes
were then probed using various antibodies and the ECL
system was used to visualize the separated proteins.
Blots were stripped and reprobed with b-actin as a load-
ing control.
Statistical analysis
Continuous data were expressed as means ± S.E.M. Com-
parisons between groups were performed by a one-way
analysis of ANOVA with post hoc analyses performed
using the Student-Newman-Keuls method. Statistical
significance was defined as P < 0.05.
Results
Metabolic parameters changes in fructose-treated rats
All rats in the study were assessed for a variety of phy-
siological parameters 3 weeks after receiving either con-
trol or fructose-containing drinking water. As expected,
consumption of fructose-containing water resulted in
significantly increased levels of serum insulin and serum
triglyceride, and significantly decreased urine osmolarity
(all P < 0.05) (Table 1). Insulin resistance (HOMA-IR)
was also significantly increased in fructose-treated rats
(P < 0.05). These data indicate that fructose administra-
tion induced insulin resistance, and hypoosmolar diur-
esis as described previously [11].
Effects of CYP2J3 gene delivery on CYP2J3 protein
expression
There weeks after gene delivery (i.e. at week 6 of the
study), CYP2J3 protein levels were increased in the aorta,
heart, liver and kidney of fructose-treated CYP2J3(+)
(F+CYP2J3(+)) rats compared to fructose-treated rats
(Figure 1A). Importantly, CYP2J3 functionality was
demonstrated by the nearly 4-fold increase in plasma and
urinary 14,15-DHET levels in rats injected with CYP2J3
(+) compared to those in normal group (Figure 1B and
1C). Administration with L-NMMA had no significant
effects on plasma and urinary 14,15-DHET levels as
shown in Figure 1B and 1C. These data indicate that
CYP2J3 was successfully and efficiently expressed in
experimental animals.
Effects of L-NMMA administration on fructose-induced
hypertension and pathophysiological changes in rats
As expected, consumption of fructose-containing water
resulted in significantly increased levels of blood pres-
sure, and injection of CYP2J3 to fructose-treated rats
resulted in decreased systolic blood pressure 2 and 3
weeks after injection (i.e. at weeks 5 and 6 of the study)
compared to that observed in fructose-treated rats
(Figure 2). Administration of L-NMMA to fructose-trea-
ted rats resulted in increased systolic blood pressure
compared to that observed in fructose-treated rats
(Figure 2) (P < 0.05). Interestingly, administration of
L-NMMA significantly prevented the decrease in blood
pressure levels induced by CYP2J3 overexpression in
fructose-treated rats (Figure 2) (P < 0.05). These data
indicate that CYP2J3 gene delivery significantly
decreased systolic blood pressure in fructose-treated rats
at least in part through eNOS related signal pathways.
Other physiological and biochemical parameters
related to hyperinsulinemia were assessed in 10 rats per
experimental group 3 weeks after gene delivery (week 6)
(Table 2). Compared to values in the normal group,
serum insulin, insulin resistance (HOMA-IR) and serum
triglycerides were all higher, while urine osmolarity was
lower in fructose-treated rats (all P < 0.05) (Table 2).
With the exception of serum triglyceride levels, all of
these changes were prevented by CYP2J3 gene delivery
in rats with fructose-treated (Table 2). Interestingly,
administration of L-NMMA significantly and partially
reversed the effects of CYP2J3 gene delivery on serum
insulin, insulin resistance (HOMA-IR) and urine osmo-
larity in fructose-treated rats (all P < 0.05) (Table 2).
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These data indicate that CYP2J3 overexpression mark-
edly attenuated fructose-induced insulin resistance in
rats at least in part through eNOS related signal
pathways.
Effects of L-NMMA administration on eNOS expression
and activity in rats
As expected, compared to expression in corresponding
control animals, eNOS protein expression was down-
regulated in aorta, liver and skeletal muscle in fructose-
treated rats (Figure 3A, 3B and 3C), and this effect was
not observed in fructose-treated rats injected with
CYP2J3 (Figure 3A, 3B and 3C). Interestingly, adminis-
tration of L-NMMA didn’t affect eNOS expression in
aorta, liver and skeletal muscle in fructose-treated rats
(Figure 3A, 3B and 3C). Importantly, fructose intake
markedly reduced serum NO levels, and administration
of L-NMMA further decreased serum NO levels as
shown in Figure 3D. Interestingly, CYP2J3 gene delivery
significantly reversed the changes in NO levels induced
by fructose, and administration of L-NMMA signifi-
cantly and completely abolished the beneficial effects of
CYP2J3 gene delivery on NO levels (Figure 3D). These
data suggest that administration of L-NMMA blocked
eNOS activity, and didn’t affect eNOS expression.
Effects of L-NMMA administration on intracellular
signaling pathways in rats
To investigate potential mechanisms underlying the
observed effects of L-NMMA administration on improved
insulin resistance by CYP2J3 gene delivery in fructose-
treated rats. The protein expression levels of a variety of
intracellular signaling pathway molecules were investi-
gated in liver and skeletal muscle of rats in all treatment
groups 3 weeks following gene delivery. The related signal-
ing molecules that were assessed included phosphorylated
IRS-1(IRS-1-Tyr(P)989 and IRS-1-Tyr(P)307), PI3K,
P-AKT and P-AMPK.
As expected, phospho-Y989-IRS-1 levels were similarly
decreased in liver and skeletal muscle, whereas phos-
pho-S307-IRS-1 was significantly increased (data not
shown). CYP2J3 gene delivery significantly reversed the
changes in IRS-1 and phospho-IRS-1 levels induced by
fructose both in liver and skeletal muscle (data not
shown), and interestingly, administration of L-NMMA
significantly partially abolished the beneficial effects of
CYP2J3 gene delivery on IRS-1 and phospho-IRS-1
expression levels induced by fructose in rats.
A similar pattern of expression was observed for all the
molecules except IRS-1 and phospho-IRS-1 expression
levels in all tissues that were examined. Specifically, as
expected, tissue protein levels of the specified signaling
molecules were significantly decreased in fructose-treated
rats compared to levels in rats of normal group respec-
tively. The only fructose-treated rats in which these
decreases were not observed were those that were with
CYP2J3 gene delivery. PI3K and P-AKT level data for rat
liver and skeletal muscle are shown in Figure 4A and 4B,
and for P-AMPK are shown in Figure 4C. CYP2J3 gene
delivery reversed changes in protein expression and phos-
phorylation induced by fructose in rats. Interestingly,
administration of L-NMMA significantly partially abol-
ished the beneficial effects of CYP2J3 gene delivery on pro-
tein expression and phosphorylation induced by fructose
in rats. These data indicated that CYP2J3 gene delivery sig-
nificantly improved insulin resistance induced by fructose
in rats at least in part through eNOS related signal
pathways.
Discussion
This study was undertaken to examine the roles of eNOS
in CYP2J3 gene delivery reducing blood pressure and
improving insulin resistance in fructose-induced insulin
resistant rats. Results showed that a single intravenous
injection of CYP2J3 in the eukaryotic expression plasmid
pcDNA reduced blood pressure and improved sensitivity
to insulin in peripheral tissues and organs in fructose-fed
rats. Furthermore, administration of eNOS inhibitor L-
NMMA significantly and partially abolished the beneficial
effects of CYP2J3 gene delivery on hypertension and insu-
lin resistance induced by fructose intake, and possible
mechanism is associated with increased ET-1, ETA-recep-
tor mRNA expression (data not shown) and reduced sen-
sitivity of insulin to peripheral tissues and organs. These
Table 1 Physiological parameters determined in rats after 3 weeks of administration of control or fructose-containing
drinking water
Variable Control Group (n = 10) Fructose-treated Group (n = 40)
Glucose (mmol/l) 4.29 ± 0.2 5.22 ± 0.23
Insulin (mIU/l) 9.51 ± 0.39 18.21 ± 1.99**
HOMA-IR 1.71 ± 0.56 4.14 ± 2.69**
Triglyceride (mmol/l) 0.47 ± 0.06 1.06 ± 0.08*
Urine osmolarity (mOsml/Kg H2O) 826 ± 110 427 ± 33.69**
Body weight (g) 212 ± 36 334.18 ± 56.74
Values shown are mean ± SEM. *P < 0.05 vs. control group; **P < 0.001 vs. control group.
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Figure 1 Effects of CYP2J3 gene delivery on CYP2J3 protein expression, plasma and urinary 14,15-DHET levels. A, CYP2J3 protein levels
were increased in aorta, heart, liver and kidney of fructose-treated rats 3 weeks following injection of CYP2J3(+).B, Plasma 14,15-DHET levels
were increased in fructose-treated rats injected with CYP2J3(+) compared to rats in Fructose group. C, Urinary 14,15-DHET levels were increased
in fructose-treated rats injected with CYP2J3(+) compared to rats in Fructose group. *P < 0.05 vs. normal group or fructose group; n = 10 per
group. Values shown are mean ± SEM from each group of rats, respectively.
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Figure 2 Effects of L-NMMA on fructose-induced hypertension with CYP2J3 gene delivery in rats. The elevation of systolic blood pressure
observed in fructose-treated rats was decreased 1, 2 and 3 weeks after injection of CYP2J3(+) (at weeks 4, 5 and 6 of the study). Administration
of L-NMMA significantly increased blood pressure in rats of Fructose group. Interestingly, administration of L-NMMA significantly increased blood
pressure in rats of Fructose+pcDNA-2J3(+) group. Values shown are mean ± SEM from each group of rats, respectively.*P < 0.05 compared to
rats treated without fructose, #P < 0.05 compared to rats treated with fructose, **P < 0.05 compared to rats in Fructose + pcDNA-CYP2J3(+)
group; n = 4 to 10 per group per time point.












Glucose (mmol/L) 4.56 ± 0.68 5.04 ± 0.62 6.43 ± 1.09 5.84 ± 0.42 6.55 ± 0.84
Insulin (mIU/L) 9.65 ± 0.83 23.84 ±
1.37*
25.41 ± 3.25 6.24 ± 0.33# 22.54 ± 0.99**
HOMA-IR 1.85 ± 0.32 5.34 ± 0.38* 7.26 ± 0.56 1.62 ± 0.42# 6.56 ± 0.28**
Triglyceride (mmol/L) 0.56 ± 0.32 1.23 ± 0.17* 1.06 ± 0.17 1.19 ± 0.24# 1.14 ± 0.28
Urine osmolarity (mOsml/Kg
H2O)
857 ± 101 377.4 ±
69.95*
346.14 ± 34.24 763 ± 54.49# 258 ± 48.68**
Body weight (g) 273 ± 30 356 ± 29.3 347 ± 35 332 ± 19.7 379 ± 20
Values shown are mean ± SEM. *P < 0.05 vs. Normal group; #P < 0.05 vs. Fructose group; **P < 0.05 vs. Fructose+ pcDNA-CYP2J3(+) group.
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Figure 3 Effects of L-NMMA administration on eNOS expression and activity. Levels of eNOS expression in aorta (A), liver (B) and muscle
(C) were assessed by western blot at week 6 of the study. Serum NO levels (D) were determined by Griess method at week 6 of the study.
Representative western blot of eNOS and corresponding densitometric quantification of three experiments are shown. Values shown are mean ±
SEM. *P < 0.05 vs. Normal group; #P < 0.05 vs. Fructose group; **P < 0.05 vs. Fructose+ pcDNA-CYP2J3(+) group.
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Figure 4 Effects of CYP2J3 gene delivery on activation of rat insulin receptor signaling and AMPK phosphorylation. Levels of, PI3K and
P-AKT in liver (A) and muscle (B), and P-AMPK in liver and muscle (C) were assessed by western blot at week 6 of the study. Representative
western blot of protein above and corresponding densitometric quantification of three experiments are shown. Values shown are mean ± SEM.
*P < 0.05 vs. Normal group; #P < 0.05 vs. Fructose group; **P < 0.05 vs. Fructose+ pcDNA-CYP2J3(+) group.
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data provide direct evidence that CYP2J3-derived EETs
may alleviate insulin resistance at least in part through
upregulated eNOS expression.
Recent studies indicate that cytochrome P450 (CYP)
epoxygenase decreased blood pressure in various hyper-
tensive animal models. Overexpression of P450 epoxy-
genases attenuates the development of hypertension and
improves cardiac function in spontaneous hypertensive
rats [12]. CYP2J2 and CYP2C8 transgenic mice demon-
strated lower mean arterial pressure during coadministra-
tion of N-nitro-l-arginine methyl ester and indomethacin
[13]. In another experiment, a high-salt diet and subcuta-
neous angiotensin II was administered over 4 week. The
angiotensin/high-salt-induced increase in systolic blood
pressure, proteinuria, and glomerular injury was signifi-
cantly attenuated in CYP2J2 and CYP2C8 transgenic
mice compared to wild-type controls [13]. Interestingly,
increases in plasma trans-EETs by the inhibition of solu-
ble epoxide hydrolase markedly reduced blood pressure
in spontaneously hypertensive rats [14]. In contrast,
blood pressure increased significantly in female mice
lacking cytochrome P450 2J5 [15]. Overexpression of
P450 epoxygenases resulted in increased aortic eNOS
expression in vivo and in vitro, and its possible mechan-
isms were associated with the activation of MAPK and
protein kinase C signaling pathways [7]. Interestingly,
further study indicated that CYP epoxygenase metabo-
lites EETs-induced up-regulation of eNOS phosphoryla-
tion and expression appears to involve in both PI3K/Akt
and MAPK pathways [8]. CYP epoxygenase-derived eico-
sanoids are vasodilatory, largely through their ability to
activate eNOS and NO release [16]. From the data
described above, we can see that CYP epoxygenase and
its metabolites EETs decrease blood pressure in some
hypertensive animal models at least in part through
increased eNOS expression and activity. Our recent data
suggest that CYP2J3 gene delivery significantly reduced
blood pressure in fructose-treated rats, however, whether
CYP2J3 gene delivery reduces blood pressure partially by
the upregulation of eNOS remains to be further eluci-
dated. In this study, we found that administration of
eNOS inhibitor L-NMMA significantly and partially abol-
ished the beneficial effects of CYP2J3 gene delivery on
hypertension induced by fructose intake, and its possible
mechanism is associated with increased ET-1, ETA-
receptor mRNA expression (data not shown). These data
demonstrated that CYP2J3 gene delivery significantly
reduced blood pressure at least in part through the upre-
gulation of eNOS in fructose-treated rats.
Previous experimental evidence suggests that NO is
involved in the pathogenesis of insulin resistance and
diabetes [17,18]. Molecular genetic study demonstrated
that CYP2J2 G-50T polymorphism may contribute to
the pathogenesis of type 2 diabetes, partially by effects
on insulin resistance, in patients with younger onset
type 2 diabetes [19]. Furthermore, Recent data indicate
that reduced NO-cGMP signaling contributes to vascu-
lar inflammation and insulin resistance induced by high-
fat feeding [20]. In contrast, increased eNOS expression
reduces hyperinsulinemia and improves insulin resis-
tance in fructose-treated rats [5]. Our recent data sug-
gest that CYP2J3 gene delivery significantly improved
insulin resistance in fructose-treated rats, however,
whether CYP2J3 gene delivery improves insulin resis-
tance partially by the upregulation of eNOS remains to
be further elucidated. Previous data demonstrate that
eNOS overexpression activates the IRS-1/PI3K/AKT sig-
nalling pathways, which indicate that eNOS overexpres-
sion activates insulin/insulin receptor-related signaling
pathways and suggest that eNOS may potentiate insulin
receptor signaling in muscles and thus improve insulin
sensitivity [5]. Small molecule-mediated activation of
AMPK improves insulin resistance in ob/ob mice [21]
and represents a promising approach for the treatment
of type 2 diabetes and the metabolic syndrome [22].
Interestingly, eNOS overexpression significantly
increased AMPK phosphorylation in fructose-treated
rats [5]. In this study, we found that administration of
eNOS inhibitor L-NMMA significantly and partially
abolished the beneficial effects of CYP2J3 gene delivery
on insulin resistance induced by fructose intake, which
is supported by the results of recent study that increased
NO availability attenuates high fat diet induced meta-
bolic alterations and gene expression associated with
insulin resistance [23], and its possible mechanism is
associated with inhibited IRS-1/PI3K/AKT and AMPK
signalling pathways. These data demonstrated that
CYP2J3 gene delivery significantly improved insulin
resistance at least in part through the upregulation of
eNOS in fructose-treated rats.
In conclusion, we have demonstrated that CYP2J3
gene delivery significantly reduced hypertension and
improved insulin resistance at least in part through the
upregulation of eNOS expression in fructose-treated
rats. These effects were associated with decreased ET-1
and ETA mRNA expression in aorta and activation of
the IRS-1/PI3K/AKT and AMPK signaling pathways in
liver and muscle. The ability of CYP epoxygenase deliv-
ery to exert a broad spectrum of beneficial effects is
mainly attributed to the activation of eNOS related sig-
nalling pathways, and warrants further investigation of
this approach in the treatment of hypertension asso-
ciated with insulin resistance and diabetes in humans.
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